open access

Ahead of Print
ORIGINAL ARTICLES
Published online: 2019-03-05
Submitted: 2018-12-06
Accepted: 2019-02-07
Get Citation

Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study

Abdurrahman Çetin, Engin Deveci
DOI: 10.5603/FM.a2019.0029
·
Pubmed: 30835336

open access

Ahead of Print
ORIGINAL ARTICLES
Published online: 2019-03-05
Submitted: 2018-12-06
Accepted: 2019-02-07

Abstract

Traumatic brain injury leads to neuronal damage and neurological dysfunction. The aim of our study was to investigate the antioxidative effect of Honokiol on traumatic brain injury in rats with biochemical, histopathological and immunohistochemical methods. Sprague–Dawley rats were subjected to traumatic brain injury with a weight-drop device using 300g/1m weight/height impact. Fourty five rats were divided into three groups as control group, traumatic brain injury (TBI) group and TBI + Honokiol group (5 mg/kg/day, i.p.). Honokiol (5 mg/kg) dissolved in dimethyl sulfoxide (DMSO) was intraperitoneally administered to rats for 7 days after the trauma. At the end of experiment, blood samples were taken from the animals and analyzed with various biochemical markers. Histopathological examination of the trauma group revealed some degenerated pyramidal cells, dilatation and congestion in blood vessels, hyperplasia in endothelial cells, inflammatory cell infiltration around the vein and disruptions in glial extensions. In TBI + Honokiol group, pyramidal neurons showed a decrease in degeneration, slight dilatation in blood vessels, improvement of endothelial cells towards the lumen, and reduction of inflammatory cells in the vessel. In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels. In the blood brain barrier deteriorated after trauma, it was observed that the glial foot processes were positive expression and extended to the endothelial cells in the TBI + Honokiol group.

Glial fibrillary acidic protein (GFAP) expression showed a positive reaction in these processes. Considering the important role of antioxidants and inflammatory responses in cerebral damage induced by traumatic head injury, honokiol is thought to be important in decreasing lipid peroxidation, protecting the membrane structure of blood brain barrier, degeneration of neurons and glial cells.

Abstract

Traumatic brain injury leads to neuronal damage and neurological dysfunction. The aim of our study was to investigate the antioxidative effect of Honokiol on traumatic brain injury in rats with biochemical, histopathological and immunohistochemical methods. Sprague–Dawley rats were subjected to traumatic brain injury with a weight-drop device using 300g/1m weight/height impact. Fourty five rats were divided into three groups as control group, traumatic brain injury (TBI) group and TBI + Honokiol group (5 mg/kg/day, i.p.). Honokiol (5 mg/kg) dissolved in dimethyl sulfoxide (DMSO) was intraperitoneally administered to rats for 7 days after the trauma. At the end of experiment, blood samples were taken from the animals and analyzed with various biochemical markers. Histopathological examination of the trauma group revealed some degenerated pyramidal cells, dilatation and congestion in blood vessels, hyperplasia in endothelial cells, inflammatory cell infiltration around the vein and disruptions in glial extensions. In TBI + Honokiol group, pyramidal neurons showed a decrease in degeneration, slight dilatation in blood vessels, improvement of endothelial cells towards the lumen, and reduction of inflammatory cells in the vessel. In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels. In the blood brain barrier deteriorated after trauma, it was observed that the glial foot processes were positive expression and extended to the endothelial cells in the TBI + Honokiol group.

Glial fibrillary acidic protein (GFAP) expression showed a positive reaction in these processes. Considering the important role of antioxidants and inflammatory responses in cerebral damage induced by traumatic head injury, honokiol is thought to be important in decreasing lipid peroxidation, protecting the membrane structure of blood brain barrier, degeneration of neurons and glial cells.

Get Citation

Keywords

traumatic brain injury, Honokiol, vascular endothelial growth factor (VEGF), glial fibrillary acidic protein, rat

About this article
Title

Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study

Journal

Folia Morphologica

Issue

Ahead of Print

Published online

2019-03-05

DOI

10.5603/FM.a2019.0029

Pubmed

30835336

Keywords

traumatic brain injury
Honokiol
vascular endothelial growth factor (VEGF)
glial fibrillary acidic protein
rat

Authors

Abdurrahman Çetin
Engin Deveci

References (53)
  1. Baldwin SA, Gibson T, Callihan CT, et al. Neuronal cell loss in the CA3 subfield of the hippocampus following cortical contusion utilizing the optical disector method for cell counting. J Neurotrauma. 1997; 14(6): 385–398.
  2. Baloğlu M, Çetin A, Tuncer MC. Neuroprotective effects of Potentilla fulgens on spinal cord injury in rats: an immunohistochemical analysis. Folia Morphol. 2018 [Epub ahead of print].
  3. Blennow K, Hardy J, Zetterberg H. The neuropathology and neurobiology of traumatic brain injury. Neuron. 2012; 76(5): 886–899.
  4. Chao LK, Liao PC, Ho CL, et al. Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem. 2010; 58(6): 3472–3478.
  5. Chiang J, Shen YC, Wang YH, et al. Honokiol protects rats against eccentric exercise-induced skeletal muscle damage by inhibiting NF-kappaB induced oxidative stress and inflammation. Eur J Pharmacol. 2009; 610(1-3): 119–127.
  6. Chodobski A, Chung I, Koźniewska E, et al. Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury. Neuroscience. 2003; 122(4): 853–867.
  7. Chuang DY, Chan MH, Zong Y, et al. Magnolia polyphenols attenuate oxidative and inflammatory responses in neurons and microglial cells. J Neuroinflammation. 2013; 10: 15.
  8. Coles JP. Regional ischemia after head injury. Curr Opin Crit Care. 2004; 10(2): 120–125.
  9. Diaz-Arrastia R, Kochanek PM, Bergold P, et al. Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. J Neurotrauma. 2014; 31(2): 135–158.
  10. Dore-Duffy P, Wang X, Mehedi A, et al. Differential expression of capillary VEGF isoforms following traumatic brain injury. Neurol Res. 2007; 29(4): 395–403.
  11. Feng Y, Cui Y, Gao JL, et al. Neuroprotective effects of resveratrol against traumatic brain injury in rats: Involvement of synaptic proteins and neuronal autophagy. Mol Med Rep. 2016; 13(6): 5248–5254.
  12. Greve MW, Zink BJ. Pathophysiology of traumatic brain injury. Mt Sinai J Med. 2009; 76(2): 97–104.
  13. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. Trends Pharmacol Sci. 2015; 36(7): 471–480.
  14. Hakan T, Toklu HZ, Biber N, et al. Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability. Neurol Res. 2010; 32(6): 629–635.
  15. Hausmann R, Riess R, Fieguth A, et al. Immunohistochemical investigations on the course of astroglial GFAP expression following human brain injury. Int J Legal Med. 2000; 113(2): 70–75.
  16. Hayashi T, Saito A, Okuno S, et al. Damage to the endoplasmic reticulum and activation of apoptotic machinery by oxidative stress in ischemic neurons. J Cereb Blood Flow Metab. 2005; 25(1): 41–53.
  17. Hillegass LM, Griswold DE, Brickson B, et al. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods. 1990; 24(4): 285–295.
  18. Kim BH, Cho JY. Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol Sin. 2008; 29(1): 113–122.
  19. Krum JM, Khaibullina A. Inhibition of endogenous VEGF impedes revascularization and astroglial proliferation: roles for VEGF in brain repair. Exp Neurol. 2003; 181(2): 241–257.
  20. Kuribara H, Kishi E, Kimura M, et al. Comparative assessment of the anxiolytic-like activities of honokiol and derivatives. Pharmacol Biochem Behav. 2000; 67(3): 597–601.
  21. Kuribara H, Stavinoha WB, Maruyama Y. Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. J Pharm Pharmacol. 1999; 51(1): 97–103.
  22. Lee S, Park S, Won J, et al. The Incremental Induction of Neuroprotective Properties by Multiple Therapeutic Strategies for Primary and Secondary Neural Injury. Int J Mol Sci. 2015; 16(8): 19657–19670.
  23. Lenzlinger PM, Saatman KE, Hoover RC, et al. Inhibition of vascular endothelial growth factor receptor (VEGFR) signaling by BSF476921 attenuates regional cerebral edema following traumatic brain injury in rats. Restor Neurol Neurosci. 2004; 22(2): 73–79.
  24. Lim SW, Wang CC, Wang YH, et al. Microglial activation induced by traumatic brain injury is suppressed by postinjury treatment with hyperbaric oxygen therapy. J Surg Res. 2013; 184(2): 1076–1084.
  25. Lin JW, Chen JT, Hong CY, et al. Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway. Neuro Oncol. 2012; 14(3): 302–314.
  26. Lin YR, Chen HH, Lin YC, et al. Antinociceptive actions of honokiol and magnolol on glutamatergic and inflammatory pain. J Biomed Sci. 2009; 16: 94.
  27. Liou KT, Lin SM, Huang SS, et al. Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med. 2003; 69(2): 130–134.
  28. Liou KT, Shen YC, Chen CF, et al. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res. 2003; 992(2): 159–166.
  29. Liou KT, Shen YC, Chen CF, et al. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol. 2003; 475(1-3): 19–27.
  30. Lo YC, Teng CM, Chen CF, et al. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol. 1994; 47(3): 549–553.
  31. Marmarou A, Foda MA, van den Brink W, et al. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg. 1994; 80(2): 291–300.
  32. Missler U, Wiesmann M, Wittmann G, et al. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999; 45(1): 138–141.
  33. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol. 2007; 179(2): 753–763.
  34. Nag S, Takahashi JL, Kilty DW. Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma. J Neuropathol Exp Neurol. 1997; 56(8): 912–921.
  35. Nakano N, Matsuda S, Ichimura M, et al. PI3K/AKT signaling mediated by G protein‑coupled receptors is involved in neurodegenerative Parkinson's disease (Review). Int J Mol Med. 2017; 39(2): 253–260.
  36. Ou HC, Chou FP, Lin TM, et al. Protective effects of honokiol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Chem Biol Interact. 2006; 161(1): 1–13.
  37. Özevren H, Irtegün S, Deveci E, et al. Neuroprotective effects of Potentilla fulgens on traumatic brain injury in rats. Anal Quant Cytol Histol. 2017; 39: 35–44.
  38. Preston GW, Phillips DH. Quantification of a peptide standard using the intrinsic fluorescence of tyrosine. Anal Bioanal Chem. 2016; 408(9): 2187–2193.
  39. Scheff SW, Price DA, Hicks RR, et al. Synaptogenesis in the hippocampal CA1 field following traumatic brain injury. J Neurotrauma. 2005; 22(7): 719–732.
  40. Shultz SR, McDonald SJ, Vonder Haar C, et al. The potential for animal models to provide insight into mild traumatic brain injury: Translational challenges and strategies. Neurosci Biobehav Rev. 2017; 76(Pt B): 396–414.
  41. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7–35.
  42. Sohrab G, Angoorani P, Tohidi M, et al. Pomegranate (Punicagranatum) juice decreases lipid peroxidation, but has no effect on plasma advanced glycated end-products in adults with type 2 diabetes: a randomized double-blind clinical trial. Food Nutr Res. 2015; 59: 28551.
  43. Stroop R, Thomale UW, Päuser S, et al. Magnetic resonance imaging studies with cluster algorithm for characterization of brain edema after controlled cortical impact injury (CCII). Acta Neurochir Suppl. 1998; 71: 303–305.
  44. Sulakhiya K, Kumar P, Gurjar SS, et al. Beneficial effect of honokiol on lipopolysaccharide induced anxiety-like behavior and liver damage in mice. Pharmacol Biochem Behav. 2015; 132: 79–87.
  45. Talarek S, Listos J, Barreca D, et al. Neuroprotective effects of honokiol: from chemistry to medicine. Biofactors. 2017; 43(6): 760–769.
  46. Ucar T, Tanriover G, Gurer I, et al. Modified experimental mild traumatic brain injury model. J Trauma. 2006; 60(3): 558–565.
  47. Wang H, Liao Z, Sun X, et al. Intravenous administration of Honokiol provides neuroprotection and improves functional recovery after traumatic brain injury through cell cycle inhibition. Neuropharmacology. 2014; 86: 9–21.
  48. Wang X, Duan X, Yang G, et al. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One. 2011; 6(4): e18490.
  49. Xu Q, Yi LT, Pan Y, et al. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(3): 715–725.
  50. Yuan TM, Yu HM, Gu WZ, et al. Expression of glial fibrillary acidic protein in developing rat brain after intrauterine infection. Neuropathology. 2004; 24(2): 136–143.
  51. Zhang Le, Deng M, Zhou S. Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular leakage in rats via the ROS-HIF-VEGF pathway. Pharmacology. 2011; 87(5-6): 265–273.
  52. Zhang P, Liu X, Zhu Y, et al. Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-κB activation and cytokine production of glial cells. Neurosci Lett. 2013; 534: 123–127.
  53. Zhou PH, Hu W, Zhang XB, et al. Protective Effect of Adrenomedullin on Rat Leydig Cells from Lipopolysaccharide-Induced Inflammation and Apoptosis via the PI3K/Akt Signaling Pathway ADM on Rat Leydig Cells from Inflammation and Apoptosis. Mediators Inflamm. 2016; 2016: 7201549.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl